Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute

Místní automatický překlad · Původní jazyk zdroje

Illustration generated by Business News; it is not a source photograph.

Shrnutí

OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…

Původní jazyk zdroje: PR Newswire UK — News ReleasesPřečíst originál →